This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CardioNet, Inc. Reports Second Quarter 2011 Financial Results

“We are committed to building value for our shareholders through the implementation of our business strategy and organizational goals for 2011. We continue to invest for volume growth with additional sales and marketing resources, as well as by expanding our commercial reimbursement for MCOT TM. We are excited to begin commercialization of our next generation MCOT TM platform, C5, during the second half of the year. C5 will reduce our overall cost structure and provide additional ease-of-use features for our patients. Our MCOT™ technology provides meaningful benefits for physicians, patients and payors, and we remain dedicated to expanding adoption and driving future growth and profitability.”

Second Quarter Financial Results

Revenue for the second quarter 2011 was $31.6 million, a decrease of 0.9% compared to $31.9 million in the second quarter 2010. The decrease in revenue was primarily due to lower average MCOT TM reimbursement, as well as slightly lower MCOT TM volume which the Company is addressing through increased investment in sales and marketing. This decrease was partially offset by the inclusion of Biotel revenue. For the three months ended June 30, 2011, patient revenue was comprised of 37% Medicare and 63% commercial, and patient volume was comprised of 51% Medicare and 49% commercial.

Gross profit for the second quarter 2011 decreased to $18.6 million, or 58.9% of revenue, compared to $20.1 million, or 62.9% of revenue, in the second quarter 2010. The decline in gross profit is related to the lower average MCOT TM reimbursement, as well as the addition of the lower margin Biotel business.

On a GAAP basis, operating expenses for the second quarter 2011 were $21.7 million, a decrease of 2.7% compared to $22.3 million in the second quarter 2010. Operating expenses on an adjusted basis declined by 3.4% compared to the prior year quarter, excluding $1.8 million in the second quarter 2011 and $1.7 million in the second quarter 2010 related to restructuring and other nonrecurring charges. The decrease in operating expenses was driven by a reduction in bad debt expense, as well as the Company’s cost reduction initiatives that were implemented in early 2010. These reductions were partially offset by the addition of Biotel’s operating expenditures in the quarter.

2 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs